As researchers pursue innovative treatments for difficult conditions, the state of neurodevelopmental medicine is rapidly changing across the globe. Among neurodevelopmental disorders, autism spectrum disorders (ASD) are some of the most challenging disorders for families and healthcare professionals. ASD requires life long, care. ASD disrupt the ability to communicate and socially interact and decreases one’s cognitive capacity. Therefore, there is a desperate need for innovative treatments that go beyond conventional methods to assist with behavioral issues. Among the latest advances in medicine, regenerative therapies bring hope to families of children with challenging neurodevelopment disorders. Utilizing innovative therapeutic techniques, we can begin to resolve the pathophysiological processes of neurodevelopment disorders. The use of UC-MSCs therapy at Stem Cell Clinic for autistic disorders allows us to change the focus of neurodevelopment disorder therapies from symptom control to improving the patients’ quality of life.
The prominent features of the therapeutic benefits of UC-MSCs lie in their potent immunomodulatory and neurotrophic effects in autism spectrum disorders (ASD). Within their complex secretome, UC-MSCs contain several bioactive molecules that influence intercellular communication. Following their introduction to the bloodstream, UC-MSCs are able to migrate to sites of chronic neuroinflammation, where they release a variety of cytokines, chemokines, and extracellular vesicles to inhibit hyperactive microglial cells. Furthermore, UC-MSCs promote the secretion of brain-derived neurotrophic factor (BDNF), which is involved in the repair of neural tissues and the enhancement of synaptic plasticity. When combined with the anti-inflammatory modulation of the neuroinflammatory milieu via the polarization of macrophages to the anti-inflammatory phenotype and the inhibition of pro-inflammatory pathways, UC-MSCs inhibit the pathways associated with the exacerbation of symptoms of autism spectrum disorders (ASD). This complex and dynamic system of biological interactions facilitates the chronic regulation of abnormal pathways in the central nervous system.
Existing Autism Spectrum Disorders (ASD) treatment frameworks incorporate behavioral, educational and pharmacological interventions. Although these treatment approaches assist with ongoing development, there are clear restrictions with existing treatment approaches. Behavioral management approaches usually necessitate a commitment of both time and money, which are resources that a considerable number of families do not possess. Current pharmacological treatment approaches are primarily aimed at the management of irritability and/or hyperactivity. The main classes of pharmacological agents that are prescribed, including antipsychotic and stimulant agents, do not have any direct effect on the underlying biology of the disorder. Further, these agents pose a considerable burden of side effects. The absence of fundamental treatment interventions with disease-modifying or curative properties extends the reliance of patients and families on existing interventions that produce only marginal functional improvements.
The integration of UC-MSCs into a patient-centered continuum of care primarily addresses the concern of providing a disease-modifying solution with the potential to alter the course of neuroinflammatory and neuro-disconnection processes. Unlike pharmacologic autism spectrum disorders (ASD) treatments actively employed today, this biotherapy aims to promote the reestablishment of microenvironmental homeostasis in neural tissue. It has been documented that, in many of these patients, brain tissue is subjected to elevated oxidative and other types of stress. The engineered therapy delivers concentrated, bioactive, regenerative, and restorative factors to enhance normal synaptic function and white matter integrity. The dual approach of targeted neural connective tissue and peripheral immune system modulations provides a strong justification for employing this therapy. UC-MSCs at Stem Cell Clinic maintain their factory status by continuously monitoring the inner milieu of the patient and providing a customized biotherapy through proteins. This is a personalization that synthetic drugs are not able to offer.
Figure 1: Autism Spectrum Disorders (ASD) treatment paradigms
The local adoption of sophisticated cell-based therapies is underway. Thailand is becoming a leading destination for regenerative medicine due to the high-quality care at its best Stem Cell Clinics for Autism Spectrum Disorders (ASD). This is attributed to the country’s strict regulations, advanced medical infrastructures, and a growing number of professionals in the field who research and provide cutting-edge medical care. Thai clinics utilize advanced biotechnologies and provide safe, quick, and effective standardized treatments. Thai clinics’ robust medical infrastructures even allow for the long-term follow-up and assessment of various therapeutic effects. Due to the increasing collaboration between state-of-the-art research hospitals and clinics, Thailand is becoming a leader in providing advanced neuro-regenerative therapeutic interventions.
The use of UC-MSCs marks a significant development in understanding the biological drivers of autism spectrum disorders (ASD). The combination of the unique immunomodulation of these cells and the expertise of a leading Stem Cell Clinic gives practitioners the ability to offer a previously unthought-of level of functional recovery. Existing treatments offer a surface level change to outpatient behavior, but this new biological model has the potential to go beyond the neuro-chemical framework of the design and offer real change. Ethically conducted research with a solid evidence base to build on is the future of these treatments. Increasing the refinement of the application methods and expanding the clinical data sets will keep the field of regenerative medicine at the forefront of the care continuum. Clinicians and families now have a significant intervention on the working spectrum of neurodevelopmental disorders.